Parexel
 | |
| | |
| Parexel International Corp | |
|---|---|
| Type | Public / Private |
| Industry | Global biopharmaceutical service company |
| Founded | <1982> |
| Slogan | " To combine the strength of our expertise, experience and innovation to advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease" |
| Headquarters | PAREXEL International Corp., 195 West Street, Waltham, MA 02451 |
| Key people | Chairman and CEO: Josef H. von |
| Investors | NASDAQ: PRXL, S&P 400 Component |
| Number of employees | 19,370 |
Contents
History
PAREXEL International is a multinational life sciences consulting firm. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. 0verview: PAREXEL is the world's leading innovator of biopharmaceutical services. Simplify clients' journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. Committed to solving problems before they arise. To make the process smarter and more efficient. For over 35 years, PAREXEL has proven a trusted partner for the complex development journey required of biopharmaceutical and medical device companies. Post Launch
Vision: PAREXEL strives provider to the biopharmaceutical and medical device industries for the development and commercialization of new medical therapies worldwide.
Mission: PAREXEL's mission is to combine the strength of expertise, experience and innovation to advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease. [1]
TGN1412 clinical trial
In March 2006, a PAREXEL-run trial on behalf of TeGenero, the now bankrupt German biotechnology firm, on its anti-inflammatory drug TGN1412 to treat rheumatoid arthritis, multiple sclerosis or leukaemia, caused severe inflammation and multiple organ failure in six healthy volunteers at a facility based at Northwick Park Hospital in London. The drug had been tested on animals but this was the first test on humans. PAREXEL became the target of legal proceedings from lawyers representing the injured volunteers after the insurance policy of TeGenero was unable to provide sufficient compensation. When the liable company subsequently declared bankruptcy, lawyers for the volunteers initiated legal proceeding against PAREXEL and the two parties later entered into talks; the results of this meeting have not been made public. A documentary shown in the UK on 28 September 2006 featuring journalist Brian Deer as part of Channel 4's Dispatches series exposed uncertainty about the existence of data that should mandatorily have been submitted by TeGenero to the Medicines and Healthcare products Regulatory Agency (MHRA) prior to the trial indicating whether TGN1412 had been adequately tested on human blood in vitro. Concerns were also raised about whether a safe human dosage was properly obtained by TeGenero. The MHRA, however, concluded that none of the companies involved could be held responsible for the outcome of the test and that the adverse events that occurred were most likely caused by an unpredicted biological action of the drug in humans. In 1990, the firm expanded internationally and established new practice areas. By 1999 it had a staff of 4,500 and 45 offices. In the 2000s, it grew to over 18,000 employees. PAREXEL’s consulting and clinical trial work has helped establish many household drug brands and contributed to numerous successes in modern pharmacology.
In 2016, the company allied with EMC Corporation to provide a suite of regulated information and content management services. The company has announced that it will be acquired by private equity firm Pamplona Capital Management for approximately $5.0 billion. The deal is expected to close by the end of 2017.
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| November 28, 2021 | JalrOrg | Study Scavenger ICON Early Phase Services- Clinical Trial for Healthy Recreational Drug Users in Salt Lake City, UT… https://t.co/eceWaZn1FP |
| November 28, 2021 | PW_BE | Associate Project Leader - PRISM Project - Belgium - Parexel #jobs #Pharma #Hiring #Belgium #pharmiweb https://t.co/3n989QNw1o |
| November 27, 2021 | PW_DE | Parexel: Project Support - Student Opportunity
|
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
| Date | Author | Comment |
|---|---|---|
| November 28, 2021 | JalrOrg | Study Scavenger ICON Early Phase Services- Clinical Trial for Healthy Recreational Drug Users in Salt Lake City, UT… https://t.co/eceWaZn1FP |
| November 28, 2021 | PW_BE | Associate Project Leader - PRISM Project - Belgium - Parexel #jobs #Pharma #Hiring #Belgium #pharmiweb https://t.co/3n989QNw1o |
| November 27, 2021 | PW_DE | Parexel: Project Support - Student Opportunity
|
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| November 25, 2021 | Parexel | Today we are thankful for our patients. In putting #patientsfirst, we are proud to spotlight our recent Environment… https://t.co/YdOKjrhZYS |
| November 26, 2021 | Parexel | Join Ruediger Pankow, Parexel regulatory expert, alongside other industry leaders as they discuss the launch of the… https://t.co/D193nVduGo |
| November 17, 2021 | Parexel | Thanks to our CSR partner, @UnitedWay, we recently transformed five Anganwadis Centres (AWCs), improving the facili… https://t.co/7liSfypKA4 |
| November 23, 2021 | Parexel | We are proud to be the recipients of the India Workplace Equality Index 2021 bronze award. This is Parexel's 2nd co… https://t.co/szGOeapg1s |
| November 19, 2021 | Parexel | The first COVID-19 vaccine is now available for younger children. On the latest episode of the Parexel Podcast, Par… https://t.co/aGWfpS8Q7N |
Top 5 Lifetime News Headlines
Verification history
1,091 days ago- 1,091 days ago
- 1,436 days ago
- View all verifications
